Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Gary Li, Melanie Krook, Sameek Roychowdhury, Francesca Avogadri, Yining Ye and Susan Moran
Title Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors
Journal
Vol
Issue
Date
URL https://cancerres.aacrjournals.org/content/79/13_Supplement/2206
Abstract Text Cancer Res 2019;79(13 Suppl):Abstract nr 2206

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
FGFR2 FN1 FGFR2 - FN1 fusion unknown FGFR2-FN1 results from the fusion of FGFR2 and FN1 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). FGFR2-FN1 has not been characterized and therefore, the effect on protein function is unknown (PubMed, Apr 2022).
FGFR2 TTC28 FGFR2 - TTC28 fusion unknown FGFR2-TTC28 results from the fusion of FGFR2 and TTC28 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). FGFR2-TTC28 has not been characterized and therefore, the effect on protein function is unknown (PubMed, Apr 2022).
FGFR2 WDR11 FGFR2 - WDR11 fusion unknown FGFR2-WDR11 results from the fusion of FGFR2 and WDR11 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). FGFR2-WDR11 has not been characterized and therefore, the effect on protein function is unknown (PubMed, Apr 2022).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 - WDR11 stomach cancer sensitive Infigratinib Preclinical - Pdx Actionable In a preclinical study, Truseltiq (infigratinib) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of gastric cancer harboring FGFR2-WDR11 fusion (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). detail...
FGFR3 - TACC3 urinary bladder cancer predicted - sensitive Infigratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Truseltiq (infigratinib) treatment inhibited tumor growth and Erk phosphorylation in a cell line xenograft model of bladder cancer harboring FGFR3-TACC3 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). detail...
FGFR3 - TACC3 high grade glioma sensitive Infigratinib Preclinical - Pdx Actionable In a preclinical study, Truseltiq (infigratinib) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of glioma harboring FGFR3-TACC3 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). detail...
FGFR2 - FN1 liver cancer predicted - sensitive Infigratinib Preclinical - Pdx Actionable In a preclinical study, Truseltiq (infigratinib) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of liver cancer harboring FGFR2-FN1 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). detail...
FGFR2 - TTC28 cholangiocarcinoma sensitive Infigratinib Preclinical - Pdx Actionable In a preclinical study, Truseltiq (infigratinib) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of cholangiocarcinoma harboring FGFR2-TTC28 fusion (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). detail...
FGFR2 - GAB2 breast cancer predicted - sensitive Infigratinib Preclinical - Pdx Actionable In a preclinical study, Truseltiq (infigratinib) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of breast cancer harboring FGFR2-GAB2 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). detail...